Skip Navigation

Annals of Oncology 2008 19(6):1031; doi:10.1093/annonc/mdn380
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in Ann Oncol
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

in this issue

In this issue

The first 10% of the full text of this article appears below.


   ADAM-17 predicts adverse outcome in patients with breast cancer
 
ADAM-17 is a matrix metalloproteinase-like enzyme involved in the release of several ligands that have been shown to promote both cancer formation and progression, including transforming growth factor-{alpha}, amphiregulin, heparin-binding epidermal growth factor, epiregulin and tumor necrosis factor-{alpha}. Consistent with this, ADAM-17 has been implicated in tumor formation/progression; work in breast cancer cell lines in culture has shown that ADAM-17 promotes both proliferation and invasion, . . . [Full Text of this Article]


   Prognosis of advanced hepatocellular carcinoma
 

   Bortezomib, doxorubicin and dexamethasone in multiple myeloma
 

   Changes in breast cancer incidence and mortality
 

   Quote
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in Ann Oncol:

ADAM-17 predicts adverse outcome in patients with breast cancer
P. M. McGowan, E. McKiernan, F. Bolster, B. M. Ryan, A. D. K. Hill, E. W. McDermott, D. Evoy, N. O'Higgins, J. Crown, and M. J. Duffy
Ann Oncol 2008 19: 1075-1081. [Abstract] [Full Text]  

Prognosis of advanced hepatocellular carcinoma: comparison of three staging systems in two French clinical trials
S. Collette, F. Bonnetain, X. Paoletti, M. Doffoel, O. Bouché, J. L. Raoul, P. Rougier, F. Masskouri, L. Bedenne, and J. C. Barbare
Ann Oncol 2008 19: 1117-1126. [Abstract] [Full Text]  

Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma
A. Palumbo, F. Gay, S. Bringhen, A. Falcone, N. Pescosta, V. Callea, T. Caravita, F. Morabito, V. Magarotto, M. Ruggeri, I. Avonto, P. Musto, N. Cascavilla, B. Bruno, and M. Boccadoro
Ann Oncol 2008 19: 1160-1165. [Abstract] [Full Text]  

Quantification of changes in breast cancer incidence and mortality since 1990 in 35 countries with Caucasian-majority populations
C. Héry, J. Ferlay, M. Boniol, and P. Autier
Ann Oncol 2008 19: 1187-1194. [Abstract] [Full Text]